Musculoskeletal · Metabolic Bone Disease

Osteoporosis

USMLE2PANCE
7

Bets

The facts most likely to be tested

1

The gold standard for diagnosis is Dual-energy X-ray absorptiometry (DEXA) scan showing a T-score of ≤ -2.5 at the lumbar spine, femoral neck, or total hip.

Confidence:
2

Universal screening for osteoporosis is recommended for all women aged ≥ 65 years and younger postmenopausal women with equivalent fracture risk factors.

Confidence:
3

Bisphosphonates (e.g., alendronate) are the first-line pharmacologic therapy for patients at high risk of fracture to inhibit osteoclast-mediated bone resorption.

Confidence:
4

FRAX score calculation is utilized to estimate the 10-year probability of a major osteoporotic fracture to guide treatment decisions in patients with osteopenia.

Confidence:
5

Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis, requiring initiation of bisphosphonates if the patient is on long-term prednisone (≥ 2.5 mg/day for ≥ 3 months).

Confidence:
6

Denosumab, a monoclonal antibody against RANK ligand, is an effective alternative for patients who cannot tolerate oral bisphosphonates or have impaired renal function.

Confidence:
7

Vertebral compression fractures are the most common clinical manifestation, often presenting as acute back pain following minimal trauma or sudden movement.

Confidence:

Vignette unlocked

A 72-year-old postmenopausal woman presents to the clinic for a routine wellness exam. She has a history of hypertension and a remote smoking history. She reports no recent falls or trauma but notes a loss of 2 inches in height over the last 5 years and occasional mid-thoracic back pain. Physical examination reveals kyphosis of the thoracic spine. Her laboratory workup, including calcium, phosphorus, and vitamin D levels, is within normal limits.

What is the most appropriate next step in the management of this patient?

+Reveal answer

Dual-energy X-ray absorptiometry (DEXA) scan

The patient's clinical presentation of height loss and kyphosis is highly suggestive of vertebral compression fractures secondary to osteoporosis, necessitating a DEXA scan to confirm the diagnosis and quantify bone mineral density.

Mo

Depth

Full handout

High yield triage

Etiology / Epidemiology

Postmenopausal women and elderly patients with low bone mass and microarchitectural deterioration.

Clinical Manifestations

Asymptomatic until fracture; dowager's hump and loss of height are classic.

Diagnosis

DEXA scan with a T-score ≤ -2.5 is the diagnostic threshold.

Treatment

Bisphosphonates are first-line; esophagitis and osteonecrosis of the jaw are key risks.

Prognosis

Hip fractures carry the highest morbidity; 20% mortality within one year.

Full handout

Epidemiology & Etiology

Primary osteoporosis is driven by estrogen deficiency in postmenopausal women and age-related decline in osteoblast activity. Secondary causes include chronic glucocorticoid use, hyperthyroidism, and malabsorption syndromes. Caucasian/Asian ethnicity and low body mass index are major non-modifiable risk factors.

Pertinent Anatomy

Trabecular bone (cancellous) is affected earlier than cortical bone due to higher metabolic turnover. The vertebral bodies, proximal femur, and distal radius are the most common sites of fragility fractures.

Pathophysiology

An imbalance between bone resorption (osteoclasts) and bone formation (osteoblasts) leads to net bone loss. Estrogen normally inhibits osteoclast activity; its withdrawal accelerates bone turnover. The resulting porous bone structure lacks the structural integrity to withstand normal mechanical stress.

Clinical Manifestations

Patients are typically asymptomatic until a fragility fracture occurs. Physical exam may reveal dowager's hump (kyphosis) and a measurable loss of height (>2 cm). Acute back pain following minor trauma suggests a vertebral compression fracture.

Diagnosis

The DEXA scan (Dual-energy X-ray absorptiometry) is the gold standard for diagnosis. A T-score ≤ -2.5 confirms osteoporosis, while -1.0 to -2.5 indicates osteopenia. The FRAX score is used to estimate the 10-year probability of major osteoporotic fracture.

Treatment

Alendronate is the first-line therapy. Patients must remain upright for 30 minutes post-dose to avoid esophagitis. Long-term use (>5 years) requires a 'drug holiday' due to risks of atypical femoral fractures and osteonecrosis of the jaw. Calcium and Vitamin D supplementation are mandatory adjuncts.

Prognosis

Fractures lead to chronic pain, loss of independence, and increased mortality. Hip fractures are the most severe complication, often requiring surgical intervention and intensive rehabilitation. Serial DEXA scans are performed every 1-2 years to monitor treatment efficacy.

Differential Diagnosis

Osteomalacia: characterized by defective mineralization, often due to Vitamin D deficiency

Multiple Myeloma: presents with lytic lesions and elevated serum protein gap

Hyperparathyroidism: associated with elevated calcium and brown tumors

Paget Disease: shows elevated alkaline phosphatase and thickened, disorganized bone

Metastatic Bone Disease: usually presents with a known primary malignancy